Leen Kawas’s career in biotechnology has been defined by both scientific ambition and entrepreneurial resolve. Born and raised in Jordan, she built her foundation as a scientist before charting a path that would take her to the heart of the U.S. biotech industry. Along the way, she co-founded a pharmaceutical company, raised hundreds of millions of dollars, and became one of a small number of women founders to take a company public on the NASDAQ. Her story illustrates how determination and vision can move science from the laboratory to the marketplace—and, ultimately, to patients in need.
Today, Kawas serves as CEO of EIT Pharma, sits on the board of Inherent Biosciences, and is co-founder and managing general partner of Propel Bio Partners, a venture fund dedicated to life sciences. But her path began far from the boardrooms of American biotech. It began in Jordan, where her early training instilled both curiosity about biology and conviction that science could change lives.
Foundations in Science
Kawas pursued her education with a focus on pharmacy and molecular biology, disciplines that gave her both practical and theoretical grounding. She was drawn to the intersection of chemistry, biology, and medicine, seeing how discoveries at the cellular level could ripple outward into therapies that transform health.
When she moved to the United States for graduate study, she continued to deepen her expertise. That transition not only expanded her scientific training but also exposed her to the scale and ambition of the American biotech industry. It was in this environment that she began to see how research could evolve into enterprise, and how entrepreneurship could accelerate the path from bench to bedside.
Building Athira Pharma
Kawas’s most visible breakthrough came when she co-founded Athira Pharma, a company focused on therapies for neurodegenerative diseases. She recognized both the scientific urgency and the market gap: conditions such as Alzheimer’s required new treatment options, and progress had been limited.
Under her leadership, Athira advanced late-stage clinical programs and attracted significant investor support. Kawas’s ability to bridge science and business was central to the company’s momentum. By 2020, Athira went public, raising more than $400 million. The milestone placed her among only 22 women founders in the United States to take a company public, a figure that underscored both her accomplishment and the broader disparities in representation.
Challenges and Resilience
Kawas’s journey was not without challenges. The biotech industry is marked by volatility, lengthy timelines, and high risk. Clinical trials can fail despite years of preparation. Investor confidence can shift with a single data release. For a woman founder in a male-dominated sector, the hurdles are even higher.
Kawas navigated these realities with resilience. She has spoken about the importance of staying grounded in purpose, of remembering that the ultimate goal is patient impact rather than short-term market movement. Her ability to adapt while staying committed to the mission of advancing therapies reflects a leadership style shaped by both scientific rigor and entrepreneurial pragmatism.
Propel Bio Partners and Beyond
After Athira, Leen Kawas co-founded Propel Bio Partners, a venture fund designed to support life science entrepreneurs. The fund reflects her belief that biotech innovation requires more than good science—it requires capital, mentorship, and networks that can bridge discovery with delivery.
Through Propel, she has supported companies developing therapies across diverse indications, always emphasizing the need for patient relevance and scalability. Her role as an investor and mentor demonstrates a shift from leading a single company to influencing a broader ecosystem. By backing other founders, she multiplies the impact of her own journey.
Representation and Leadership
Kawas’s story also resonates as an example of representation in science and entrepreneurship. Coming from Jordan, she entered an industry where women, and particularly women of Middle Eastern origin, remain underrepresented in leadership. Her achievements highlight both the possibilities and the persistent gaps.
She has often emphasized that representation matters not as tokenism but as a pathway to broaden perspectives. Diverse leadership, she argues, leads to more resilient organizations and better decision-making. Her own presence on boards and in investment decisions underscores this principle.
A Journey Defined by Purpose
Looking back, Leen Kawas’s trajectory from Jordan to NASDAQ illustrates more than personal ambition. It represents a commitment to advancing science with tangible human impact. From early studies in pharmacy to the pressure of an IPO, her focus has remained steady: ensuring that innovation translates into therapies that improve lives.
Her remarkable journey underscores that success in biotechnology is not only about breakthroughs in the lab or milestones on the stock exchange. It is about the persistence to navigate challenges, the vision to align science with business, and the responsibility to invest in others who will continue the work.
For Leen Kawas, the story is still being written. Her leadership today at EIT Pharma, Propel Bio Partners, and Inherent Biosciences reflects a broader mission: to shape a future where biotechnology is not just an industry but a force that brings hope to patients and communities around the world.